Our studies demonstrate that cinacalcet and NPS-2143, which are allosteric CaSR activators and inactivators, respectively, can successfully rectify the loss-of-function associated with FHH2-causing Gα11 mutations and the gain-of-function associated with Gα11 mutations that lead to ADH2 or uveal melanomas (1, 11). The gene discussed is CASR; the disease is uveal melanoma.